Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension
Abdelkrim Sebkhi(Pfizer (United Kingdom)), Martin R. Wilkins(Hammersmith Hospital), Julian Strange(NIHR Bristol Cardiovascular Biomedical Research Unit), John Wharton(Pfizer (United Kingdom)), Steven C. Phillips(Pfizer (United Kingdom))
Cited by 256
Related Papers
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Mechanisms of disease: pulmonary arterial hypertension
|Nature Reviews Cardiology|2011|784
Basic Science of Pulmonary Arterial Hypertension for Clinicians
|Circulation|2010|488
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
|Circulation|2001|487